Stephan Grupp

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. doi request reprint Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 368:1509-18. 2013
  2. doi request reprint Children's Oncology Group's 2013 blueprint for research: stem cell transplantation
    Stephan A Grupp
    Children s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 4318, USA
    Pediatr Blood Cancer 60:1044-7. 2013
  3. ncbi request reprint Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 46:414-21. 2006
  4. ncbi request reprint Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day
    Stephan A Grupp
    Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 46:719-22. 2006
  5. ncbi request reprint Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma
    S A Grupp
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 18:2567-75. 2000
  6. ncbi request reprint Rapid-sequence tandem transplant for children with high-risk neuroblastoma
    S A Grupp
    Department of Pediatrics, Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Med Pediatr Oncol 35:696-700. 2000
  7. ncbi request reprint The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease
    S Shusterman
    Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 7:977-84. 2001
  8. ncbi request reprint Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
    Ginna G Laport
    Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Blood 102:2004-13. 2003
  9. ncbi request reprint Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470
    S Shusterman
    Division of Oncology, The Children s Hospital of Philadelphia, and Department of Pediatrics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4318, USA
    Med Pediatr Oncol 35:673-6. 2000
  10. ncbi request reprint Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model
    J W Stern
    Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 7:1026-32. 2001

Research Grants

  1. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2009
  2. USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
    Stephan Grupp; Fiscal Year: 2009
  3. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2007
  4. POST TRANSPLANT T CELL RECONSTITUTION IN NEUROBLASTOMA
    Stephan Grupp; Fiscal Year: 2005
  5. EVOLUTION OF B PRECURSOR LEUKEMIA IN THE EU-RET MOUSE
    Stephan Grupp; Fiscal Year: 2003
  6. Determinants of Relapse Risk After BMT for ALL
    Stephan A Grupp; Fiscal Year: 2010

Collaborators

Detail Information

Publications26

  1. doi request reprint Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 368:1509-18. 2013
    ..The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL...
  2. doi request reprint Children's Oncology Group's 2013 blueprint for research: stem cell transplantation
    Stephan A Grupp
    Children s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 4318, USA
    Pediatr Blood Cancer 60:1044-7. 2013
    ..Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN...
  3. ncbi request reprint Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 46:414-21. 2006
    ..We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur...
  4. ncbi request reprint Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day
    Stephan A Grupp
    Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 46:719-22. 2006
    ....
  5. ncbi request reprint Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma
    S A Grupp
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 18:2567-75. 2000
    ....
  6. ncbi request reprint Rapid-sequence tandem transplant for children with high-risk neuroblastoma
    S A Grupp
    Department of Pediatrics, Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Med Pediatr Oncol 35:696-700. 2000
    ..The majority of patients with high risk neuroblastoma (NB) still relapse...
  7. ncbi request reprint The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease
    S Shusterman
    Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 7:977-84. 2001
    ..We speculate that TNP-470 may be a useful adjuvant therapy for high-risk neuroblastoma patients, particularly when used in settings of minimal disease status...
  8. ncbi request reprint Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
    Ginna G Laport
    Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Blood 102:2004-13. 2003
    ....
  9. ncbi request reprint Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470
    S Shusterman
    Division of Oncology, The Children s Hospital of Philadelphia, and Department of Pediatrics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4318, USA
    Med Pediatr Oncol 35:673-6. 2000
    ..We therefore examined the efficacy of TNP-470 (TAP Pharmaceuticals, Deerfield, IL) in human neuroblastoma xenograft models...
  10. ncbi request reprint Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model
    J W Stern
    Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 7:1026-32. 2001
    ..These data indicate that inhibitors of angiogenesis do not adversely impact engraftment after stem cell transplantation...
  11. pmc Stem cell transplantation for neuroblastoma
    J D Fish
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Bone Marrow Transplant 41:159-65. 2008
    ..Research into experimental approaches to hematopoietic SCT is ongoing...
  12. ncbi request reprint An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma
    J L Powell
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 33:651-7. 2004
    ..EBV-LPD resolved in four out of five patients. We conclude that the combination of tandem SCT and CD34 selection may have increased immunosuppression in these patients to a point where there is an elevated risk of EBV-LPD...
  13. ncbi request reprint Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    Blood 105:2443-8. 2005
    ..Our data further suggest that a number of patients with ES may have ALPS, a novel finding with important therapeutic implications...
  14. pmc mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 112:2020-3. 2008
    ..We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL...
  15. ncbi request reprint Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling
    Valerie I Brown
    Division of Oncology, Department of Pathology and Laboratory Medicine, Children s Hospital of Philadelphia, and Department of Pediatrics, Division of Hematology and Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Cancer Res 67:9963-70. 2007
    ..Thus, further exploration of the IL-7Ralpha pathway may identify potential therapeutic targets in the treatment of ALL. Our data illustrate that growth-factor-mediated signaling may provide one mechanism of MTI resistance...
  16. pmc Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
    ..Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases...
  17. ncbi request reprint A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study
    Haydar Frangoul
    Department of Pediatrics, Vanderbilt University, Nashville, TN 37232 2573, USA
    Blood 110:4584-7. 2007
    ..Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD...
  18. pmc Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Divisions of Oncology and Hematology, Children s Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Blood 108:1965-71. 2006
    ..We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans...
  19. pmc Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 100:15113-8. 2003
    ..These results suggest that mammalian target of rapamycin inhibitors may be effective agents against leukemia and that one of the growth signals inhibited by this class of drugs in precursor B leukemic cells may be IL-7-mediated...
  20. pmc The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 107:1149-55. 2006
    ..We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy...
  21. ncbi request reprint Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma
    Christina M Coughlin
    Abramson Family Cancer Research Institute, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 24:5725-34. 2006
    ..In this study, our goal was to characterize the physiology of tumor immunosurveillance in children with high-risk neuroblastoma (HR-NBL)...
  22. ncbi request reprint In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
    Hisaki Fujii
    Department of Pediatrics, Division of Hematology Oncology Bone Marrow Transplantation, University of British Columbia and British Columbia s Children s Hospital, Vancouver, Canada
    Blood 109:2008-13. 2007
    ..These results suggest that CpG ODNs have potential as therapeutic agents for the treatment of ALL...
  23. ncbi request reprint RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
    Christina M Coughlin
    Division of Hematology and Oncology, Children s Hospital of Philadelphia, and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 19104, USA
    Blood 103:2046-54. 2004
    ..These findings support a novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies...
  24. pmc Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma
    Wendy L Hobbie
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:679-83. 2008
    ..We describe the clinical late effects specific to survivors of stage IV neuroblastoma all similarly treated using tandem autologous peripheral blood stem cell rescue with TBI...
  25. ncbi request reprint Role of the BCR complex in B cell development, activation, and leukemic transformation
    Susan R Rheingold
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Immunol Res 27:309-30. 2003
    ..This observation has lead directly to proposals to test drugs which may antagonize early B-cell growth signals, such as rapamycin, in acute lymphoid leukemia...
  26. ncbi request reprint High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:2891-6. 2006
    ..To provide an update on long-term survival of patients with high-risk neuroblastoma treated with tandem cycles of myeloablative therapy and peripheral-blood stem-cell rescue (PBSCR)...

Research Grants15

  1. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2009
    ..This research will look how a new drug used in bone marrow transplant, called sirolimus, may help prevent relapse in patients and study in the cells how it may act to prevent this problem. ..
  2. USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
    Stephan Grupp; Fiscal Year: 2009
    ..These studies will immediately translate to the designs of follow-up studies of these agents. ..
  3. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2007
    ..This research will look how a new drug used in bone marrow transplant, called sirolimus, may help prevent relapse in patients and study in the cells how it may act to prevent this problem. ..
  4. POST TRANSPLANT T CELL RECONSTITUTION IN NEUROBLASTOMA
    Stephan Grupp; Fiscal Year: 2005
    ..abstract_text> ..
  5. EVOLUTION OF B PRECURSOR LEUKEMIA IN THE EU-RET MOUSE
    Stephan Grupp; Fiscal Year: 2003
    ..He will immunoprecipitate Rfp-Ret from the pro B cell populations of fetal and healthy adult E(-ret mice as well as from leukemias and compare the levels of tyrosine phophorylation of Rfp-Ret and Rfp-Ret-bound proteins. ..
  6. Determinants of Relapse Risk After BMT for ALL
    Stephan A Grupp; Fiscal Year: 2010
    ..This research will look how a new drug used in bone marrow transplant, called sirolimus, may help prevent relapse in patients and study in the cells how it may act to prevent this problem. ..